Copyright
©The Author(s) 2025.
World J Clin Oncol. Sep 24, 2025; 16(9): 108585
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.108585
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.108585
Table 1 Representative positron-emitting radionuclides used in immuno-positron emission tomography for hematologic malignancies
Radionuclide | Emission | Half-life | β+ ray emitting rate |
Copper-64 (64Cu) | β+, β-, EC | 12.7 h | 19% |
Zirconium-89 (89Zr) | β+, EC | 78.4 h | 23% |
Gallium-68 (68Ga) | β+, EC | 68 min | 89% |
Table 2 Surface antigens targeted in immuno-positron emission tomography for hematologic malignancies
Types of hematologic malignancy | Surface antigens targeted in immuno-PET detection |
Non-Hodgkin lymphoma | CD19, CD20, CXCR4 |
Hodgkin lymphoma | CD30 |
Multiple myeloma | CD38, CD138, VLA-4, BCMA, SLAMF7, CXCR4 |
Acute myeloid leukemia | CD33, CXCR4 |
Acute lymphoblastic leukemia | CXCR4 |
- Citation: Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. World J Clin Oncol 2025; 16(9): 108585
- URL: https://www.wjgnet.com/2218-4333/full/v16/i9/108585.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i9.108585